The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
Open accessAbstract
Current genome-editing technologies introduce double-stranded (ds) DNA breaks at a target locus as the first step to gene correction. Although most genetic diseases arise from point mutations, current approaches to point mutation correction are inefficient and typically induce an abundance of random insertions and deletions (indels) at the target locus resulting from the cellular response to dsDNA breaks. Here we report the development of 'base editing', a new approach to genome editing that enables the direct, irreversible conversion of one target DNA base into another in a programmable manner, without requiring dsDNA backbone cleavage or a donor template. We engineered fusions of CRISPR/Cas9 and a cytidine deaminase enzyme that retain the ability to be programmed with a guide RNA, do not induce dsDNA breaks, and mediate the direct conversion of cytidine to uridine, thereby effecting a C→T (or G→A) substitution. The resulting 'base editors' convert cytidines within a window of approximately five nucleotides, and can efficiently correct a variety of point mutations relevant to human disease. In four transformed human and murine cell lines, second- and third-generation base editors that fuse uracil glycosylase inhibitor, and that use a Cas9 nickase targeting the non-edited strand, manipulate the cellular DNA repair response to favour desired base-editing outcomes, resulting in permanent correction of ~15-75% of total cellular DNA with minimal (typically ≤1%) indel formation. Base editing expands the scope and efficiency of genome editing of point mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An alternative approach is to use CRISPR-Cas9 coupled to DNA editing enzymes that catalyze targeted A-to-G or Cto-T genomic sequence changes without inducing a break in DNA, potentially reversing pathogenic single-nucleotide changes or disabling genes via the introduction of a stop codon 25,26 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Base editors are one such tool, which couple Cas9 nickases with nucleotide deaminases to achieve single nucleotide conversion without introducing DSBs.”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Komor et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The discovery of spontaneous hydrolytic deamination of cytosine converting C-G base pairs to T-A in humans highlighted the potential of base editing for direct base pair conversion without requiring double-strand breaks or homology repair templates (Komor, et al., 2016).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Komor, et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Next-generation CRISPR tools, such as base editors, use enzymes like cytidine or adenine deaminases fused to Cas9 to introduce single nucleotide variants (SNVs) without DSBs.12,13”
From Protocol to create isogenic disease models from adult stem cell-derived organoids using next-generation CRISPR tools (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the same paper, with enhanced third-generation base editors, Komor et al. achieved >30-fold greater editing efficiency in various human cell lines when compared to HDR-mediated Cas9 editing, with fewer indel formation.”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [82]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Alternatives to DNA cleavage-induced editing include using CRISPR-Cas9 for direct chemical sequence alteration (base editing) 25,26 , providing RNA templates for gene alteration (prime editing) 27,28 , and for transcriptional control (CRISPR interference, CRISPRi; CRISPR activation, CRISPRa) 29,30 (Fig. 3).”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“CBE converts cytosine to thymine”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Komor et al., 2016
The cited source says what the claim attributes to it.
In the citing paper
“First-generation base editors had limitations such as low efficiency and base excision repair (BER) activity that reversed edits (Komor et al., 2016).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Komor et al., 2016
The cited source says what the claim attributes to it.
In the citing paper
“Second-generation editors, such as APOBEC-XTEN-dCas9-UGI, added an uracil DNA glycosylase inhibitor (UGI) to improve C-to-T conversion (Komor et al., 2016) but still had <0.1% indel formation, limiting precision (Azameti and Dauda, 2021).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Komor et al., 2016
The cited source says what the claim attributes to it.
In the citing paper
“Fusion of a cytidine deaminase (rAPOBEC1) to a partially inactive nickase-Cas9(D10A) protein results in a cytidine base editor (CBE) that allows for C > T base changes via a uracil intermediate28”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“Coupling this Cas9n or dCas9, the catalytically “dead” variant of Cas9, with a cytidine deaminase enzyme enables the gRNA-mediated deamination of cytosine (C) bases in the non-target DNA strand into uracil (U), which shares the base-pairing properties of thymine (T) [82].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [82]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The second study used CRISPR-Cas9-mediated genome editing to remove a mutation in exon 23 in the mdx mouse model of DMD, providing partial recovery of functional dystrophin protein in skeletal myofibers and cardiac muscle 25,26,49 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [25]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“ABE catalyzes the editing from adenine to guanine”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Komor et al., 2016
Experimental — accuracy not yet measuredIn the citing paper
“Variations on these methods enable the functional evaluation of genes (via knockout screens124), regulatory elements (using CRISPR interference and CRISPR activation screens125,126), and genetic variants (base editors127) at increasing scale and resolution29.”
From A brief history of human disease genetics (2020) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,951
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
ClinVar: public archive of interpretations of clinically relevant variants
Landrum, M. J., Lee, J. M., Benson, M., Brown, G., Chao, C., Chitipiralla, S., Gu, B., Hart, J., Hoffman, D., Hoover, J., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1222 · Cited by 2,758
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
Rationally engineered Cas9 nucleases with improved specificity
Slaymaker, I. M., Gao, L., Zetsche, B., Scott, D. A., Yan, W. X., & Zhang, F. (2016) · Science · doi:10.1126/science.aad5227 · Cited by 2,414
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Mali, P., Aach, J., Stranges, P. B., Esvelt, K. M., Moosburner, M., Kosuri, S., Yang, L., & Church, G. M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2675 · Cited by 1,752
Cited by
Sorted by citations
Items 1,001–1,035 of 1,035
A CRISPR way for accelerating cereal crop improvement: Progress and challenges
Basu, U., Riaz Ahmed, S., Bhat, B. A., Anwar, Z., Ali, A., Ijaz, A., Gulzar, A., Bibi, A., Tyagi, A., Nebapure, S. M., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.866976 · Cited by 51
Massively parallel assessment of human variants with base editor screens
Hanna, R. E., Hegde, M., Fagre, C. R., DeWeirdt, P. C., Sangree, A. K., Szegletes, Z., Griffith, A., Feeley, M. N., Sanson, K. R., Baidi, Y., et al. (2020) · doi:10.1101/2020.05.17.100818 · Cited by 314
“CRISPR base editors (Gaudelli et al., 2017; Komor et al., 2016), which introduce transition mutations at target loci, are an attractive candidate for sub-saturating variant screening for several reasons.”
Self-citationKondo, K., & Taguchi, C. (2022) · Food Safety · doi:10.14252/foodsafetyfscj.d-21-00016 · Cited by 49
Concerns regarding ‘off-target’activity of genome editing endonucleases
Kadam, U. S., Shelake, R. M., Chavhan, R. L., & Suprasanna, P. (2018) · Plant Physiology and Biochemistry · doi:10.1016/j.plaphy.2018.03.027 · Cited by 47
Emerging applications of gene editing technologies for the development of climate-resilient crops
Chavhan, R. L., Jaybhaye, S. G., Hinge, V. R., Deshmukh, A. S., Shaikh, U. S., Jadhav, P. K., Kadam, U. S., & Hong, J. C. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1524767 · Cited by 55
“First-generation base editors had limitations such as low ef fi ciency and base excision repair (BER) activity that reversed edits (Komor et al., 2016).”
InfluentialWang, M., Krueger, J. B., Gilkey, A. K., Stelljes, E. M., Kluesner, M. G., Pomeroy, E. J., Skeate, J. G., Slipek, N. J., Lahr, W. S., Claudio Vázquez, P. N., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009560 · Cited by 45
Massively targeted evaluation of therapeutic CRISPR off-targets in cells
Pan, X., Qu, K., Yuan, H., Xiang, X., Anthon, C., Pashkova, L., Liang, X., Han, P., Corsi, G. I., Xu, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31543-6 · Cited by 42
Pattharaprachayakul, N., Lee, M., Incharoensakdi, A., & Woo, H. M. (2020) · Enzyme and Microbial Technology · doi:10.1016/j.enzmictec.2020.109619 · Cited by 43
Xiong, X., Li, Z., Liang, J., Liu, K., Li, C., & Li, J.-F. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac166 · Cited by 41
Genome engineering of stem cell organoids for disease modeling
Sun, Y., & Ding, Q. (2017) · Protein & Cell · doi:10.1007/s13238-016-0368-0 · Cited by 39
Shen, Q., Ruan, H., Zhang, H., Wu, T., Zhu, K., Han, W., Dong, R., Ming, T., Qi, H., & Zhang, Y. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1375120 · Cited by 38
Salman, A., Kantor, A., McClements, M. E., Marfany, G., Trigueros, S., & MacLaren, R. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091842 · Cited by 37
Base editing for reprogramming cyanobacterium Synechococcus elongatus
Wang, S.-Y., Li, X., Wang, S.-G., & Xia, P.-F. (2023) · Metabolic Engineering · doi:10.1016/j.ymben.2022.11.005 · Cited by 31
New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing
Oostveen, R. F., Khera, A. V., Kathiresan, S., Stroes, E. S. G., Fitzgerald, K., Harms, M. J., Oakes, B. L., & Kastelein, J. J. P. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.122.317963 · Cited by 31
Development of multiplexed orthogonal base editor (MOBE) systems
Cowan, Q. T., Gu, S., Gu, W., Ranzau, B. L., Simonson, T. S., & Komor, A. C. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02240-0 · Cited by 26
Self-citationSharma, K. K., Palakolanu, S. R., Bhattacharya, J., Shankhapal, A. R., & Bhatnagar-Mathur, P. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.999207 · Cited by 24
Carvalho, C., Lemos, L., Antas, P., & Seabra, M. C. (2023) · Frontiers in Ophthalmology · doi:10.3389/fopht.2023.1270561 · Cited by 21
Genome Editing of Veterinary Relevant Mycoplasmas Using a CRISPR-Cas Base Editor System
Ipoutcha, T., Rideau, F., Gourgues, G., Arfi, Y., Lartigue, C., Blanchard, A., & Sirand-Pugnet, P. (2022) · Applied and Environmental Microbiology · doi:10.1128/aem.00996-22 · Cited by 19
Cytosine base editing in cyanobacteria by repressing archaic Type IV uracil‐DNA glycosylase
Lee, M., Heo, Y. B., & Woo, H. M. (2023) · The Plant Journal · doi:10.1111/tpj.16074 · Cited by 15
Rodent Genetic Models of Ah Receptor Signaling
Wilson, R. H., & Bradfield, C. A. (2021) · Drug Metabolism Reviews · doi:10.1080/03602532.2021.1955916 · Cited by 16
“…with the advent of techniques like base editing and prime editing that induce editing without double stranded breaks, further improves the range of mutations and the ease with which these specific mutations may be installed(Komor et al. 2016; Gaudelli et al. 2017; Anzalone et al. 2019).”
BackgroundWang, Y., Tian, Y., Xu, D., Cheng, S., Li, W.-W., & Song, H. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2025.108516 · Cited by 17
Celotti, M., Derks, L. L. M., van Es, J., van Boxtel, R., Clevers, H., & Geurts, M. H. (2024) · STAR Protocols · doi:10.1016/j.xpro.2024.103189 · Cited by 17
Development of a base editor for convenient and multiplex genome editing in cyanobacteria
Li, X.-D., Liu, L.-M., Xi, Y.-C., Sun, Q.-W., Luo, Z., Huang, H.-L., Wang, X.-W., Jiang, H.-B., & Chen, W. (2024) · Communications Biology · doi:10.1038/s42003-024-06696-3 · Cited by 14
Current advances in CRISPR-Cas-mediated gene editing and regulation in cyanobacteria
Dong, Z., Chen, L., Wang, Y., Sun, T., & Zhang, W. (2024) · Blue Biotechnology · doi:10.1186/s44315-024-00009-3 · Cited by 16
Got mutation? ‘Base editors’ fix genomes one nucleotide at a time.
Ravindran, S. (2019) · Nature · doi:10.1038/d41586-019-03536-x · Cited by 12
Pulman, J., Botto, C., Malki, H., Ren, D., Oudin, P., De Cian, A., As, M., Izabelle, C., Saubamea, B., Forster, V., et al. (2024) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2024.102349 · Cited by 12
CRISPRmap: Sequencing-free optical pooled screens mapping multi-omic phenotypes in cells and tissue
Gu, J., Iyer, A., Wesley, B., Taglialatela, A., Leuzzi, G., Hangai, S., Decker, A., Gu, R., Klickstein, N., Shuai, Y., et al. (2023) · doi:10.1101/2023.12.26.572587 · Cited by 10
Qi, T., Fu, J., Zhang, W., Cui, W., Xu, X., Yue, J., Wang, Q., & Tian, X. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-2118 · Cited by 10
Chromatin structure and context-dependent sequence features control prime editing efficiency
Kim, S., Yuan, J. B., Woods, W. S., Newton, D. A., Perez-Pinera, P., & Song, J. S. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1222112 · Cited by 12
Engineering cyanobacteria for the production of aromatic natural products
Gu, F., Li, C., Zheng, H., & Ni, J. (2024) · Blue Biotechnology · doi:10.1186/s44315-024-00002-w · Cited by 9
A Pan-RNase Inhibitor Enabling CRISPR-mRNA Platforms for Engineering of Primary Human Monocytes
Laoharawee, K., Johnson, M. J., Lahr, W. S., Sipe, C. J., Kleinboehl, E., Peterson, J. J., Lonetree, C.-L., Bell, J. B., Slipek, N. J., Crane, A. T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179749 · Cited by 7
Could Seeking Human Germline Genome Editing Force Journeys of Transnational Care?
Kaur, A. (2020) · Multidisciplinary Journal of Gender Studies · doi:10.17583/generos.2020.5077 · Cited by 4
Cyanobacterial type I CRISPR-Cas systems: distribution, mechanisms, and genome editing applications
Zhang, Y., Yang, S., Zheng, X., & Tan, X. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1552030 · Cited by 3
Eaton, E. J., Wick, B. J., Chacón, J. S., Wang, A. J., Kluesner, M., Barnes, J. T., Kar, B., Wang, M., Johnson, M. J., Skeate, J. G., et al. (2026) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2026.102908 · Cited by 2
“13 Adenine base editor (ABE), first described in 2017, generally does not induce DSBs ( 1”
Massively parallel phenotyping of coding variants in cancer with Perturb-seq
Ursu, O., Neal, J. T., Shea, E., Thakore, P. I., Jerby-Arnon, L., Nguyen, L., Dionne, D., Diaz, C., Bauman, J., Mosaad, M. M., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01160-7 · Cited by 96
Metadata
- Authors
- Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R.
- Affiliations
- Howard Hughes Medical Institute (US)
- Corresponding author
- Liu, David R.
- Venue
- Nature
- Published
- 2016-04-20
- Volume
- 533
- Issue
- 7603
- Pages
- 420-424
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4873371
- OpenAlex
- W2336828812
- Cited by
- 5,437
- References
- 36
- Citations by year
- 2026: 564 · 2025: 660 · 2024: 664 · 2023: 719 · 2022: 681 · 2021: 614 · 2020: 540 · 2019: 408 · 2018: 338 · 2017: 182 · 2016: 61
- FWCI
- 171.45
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institute of General Medical Sciences (T32GM008313, F32 GM 106601-2, F32GM106601, F32 GM 112366-2, R01GM065400, F32GM112366)
- National Institute of Biomedical Imaging and Bioengineering (R01EB022376)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- base editing, CRISPR/Cas9, cytidine deaminase, point mutation correction, Cas9 nickase, DNA repair, guide RNA, genome editing, human disease models
- MeSH terms
- APOBEC-1 Deaminase, RNA, Guide, CRISPR-Cas Systems, Animals, Base Sequence, Cell Line, Cytidine, Cytidine Deaminase, Deoxyribonuclease I, DNA, DNA Repair, Genetic Engineering, Humans, Templates, Genetic, Uridine, Genes, p53, Genome, Point Mutation, Mice, Uracil-DNA Glycosidase, Apolipoprotein E4, DNA Cleavage, INDEL Mutation, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
